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Objectives: Thymosin a 1 (Ta1) recently gained interest as immune adjuvant
for vaccines because of its ability to modulate the T-cell/dendritic cell (DC)
axis and to improve antibody production. The objective of this study was to
determine whether Ta1 would address in vitro the response of human pri-
mary monocyte-derived DC, crucial regulators of vaccine-induced immunity,
upon exposure to different toll-like receptor (TLR) agonists or infection with
viruses or bacteria.
Methods: DC maturation and production of pro-inflammatory cytokines
were analyzed.
Results: Our data revealed a dual effect of Ta1 on DC biology upon viral or
bacterial stimulation. Interestingly, Ta1 enhanced human leukocyte
antigen (HLA)-I and II surface expression and secretion of IL-6, TNF-a and
IL-8 when DCs were treated with viral TLR3 and TLR7/8 agonists. Similarly, in
pandemic H1N1 influenza A-infected DCs, Ta1 raised the expression of matu-
ration markers and type I and III Interferon (IFN). In contrast, following bacte-
rial TLR2 and 4 stimulation, as well as upon Bacillus Calmette--Guerin
infection, the presence of Ta1 in DC cultures drastically lowered the analyzed
cellular parameters.
Conclusion: The knowledge that Ta1 pleiotropic effect might ameliorate anti-
viral immune responses and, at the same time, dampen inflammation caused
by bacterial infections could lay the groundwork for a more appropriate ther-
apeutic application of this molecule.
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1. Introduction
Thymosin a 1 (Ta1) is a naturally occurring thymic peptide first described and
characterized by Goldstein [1]. In the form of a synthetic 28-mer amino-terminal
acetylated peptide, this compound, displaying an excellent safety profile [2], has
been used worldwide as an adjuvant or immunotherapeutic agent to treat the
more disparate human diseases, including viral infections [3-5], immunodeficien-
cies [6] and malignancies [7,8].
Ta1 is a context-dependent molecule exceptionally capable of multi-targeted
interactions, for which many molecular mechanisms have been described leading
to promotion of innate and adaptive immunity [9,10]. In this regard, effects of
Ta1 were shown on different immune cell subsets, most importantly on
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subpopulations of T cells [11] and on dendritic cells
(DC) [12,13]. In particular, DC are widely distributed at vari-
ous sites throughout the body and are considered sentinels
of microbes, of which they can acquire and process antigens,
thus, becoming activated and undergoing maturation [14].
Matured DC upregulate co-stimulatory molecules and secrete
a plethora of pro-inflammatory cytokines thereby, upon
migration to regional lymph nodes, interacting and instruct-
ing T-cell differentiation and initiating cellular and humoral
immune responses.
In an effort to design effective immunotherapies and vac-
cines for treating cancer and/or infectious diseases, it is,
thus, attractive to understand and manipulate the DC activa-
tion process and, in turn, to modulate immune responses.
One of the most basic mechanisms for activation of the DC
system is through toll-like receptors (TLRs), highly conserved
pattern recognition receptors ubiquitously expressed from
epithelial to immune cells. TLRs recognize conserved struc-
tures of either non-self- or self-identity, in particular
pathogen-associated molecular patterns [15] but also endoge-
nous molecules created upon tissue injury, called damage-
associated molecular patterns [16,17]. In addition, TLRs sample
different compartments within the cells. TLRs involved in the
recognition of nucleic acids (TLR3, TLR7, TLR8 and TLR9)
of self and non-self origin are intracellularly localized within
endolysosomes, whereas other TLR family members (TLR1,
TLR2, TLR4, TLR5 and TLR6), triggered by lipidic or pro-
teic structures of microbial or danger source [17], are found at
the cell surface [18]. Interestingly, cellular localization of differ-
ent TLRs may have important consequences not only on
ligand accessibility but also on downstream signaling events
leading to diverse immune signatures.
In DC, TLR triggering by viral, bacterial or fungal patho-
gens stimulates the activation of a complex intracellular cas-
cade ultimately leading to transcription of hundreds of
genes, production of pro-inflammatory cytokines and induc-
tion of innate effector mechanisms.
Ta1, besides modulating directly DC differentiation and
functional maturation [12], was shown to regulate TLR signal-
ing at different levels mainly in murine DC, being at the inter-
section between canonical and noncanonical NF-kB and JNK/
p38/AP-1 pathways on one side [13,19] and IFN-regulatory fac-
tors on the other side [20]. Interestingly, the immunomodula-
tory effects of Ta1 on DC correlated with a therapeutic
effect in experimental fungal or viral infections [13,20].
Because of the key role of this cell type in the promotion of
vaccine-induced immunity, we recently demonstrated the effi-
cacy of a human primary DC-based in vitro setting to test the
immunogenicity of vaccine candidates by studying the live-
attenuated Mycobacterium tuberculosis SO2 strain, recently
entered in clinical trial [21].
Collectively, these evidences provided a solid scientific
ground for testing Ta1 as a DC-directed adjuvant for novel
vaccines or therapies. This is also in light of the increasing
interest gained in recent years by Ta1 as immune adjuvant
for vaccines [22]. In particular, Ta1 therapeutic action was
examined for its potential to enhance influenza virus (Flu)
vaccine responses in difficult-to-treat individuals, such as
those immune-suppressed due to age or hemodialysis, given
that, despite a largely diffuse vaccination protocol, this virus
still remains a prominent cause of morbidity and mortality
in these populations [23]. Flu infection, directly or indirectly
either by promoting bacterial super-infection leading to sec-
ondary pneumonia, principally caused by Streptococcus
pneumonia or Staphylococcus aureus, or exacerbating cardiovas-
cular diseases, is indeed considered a major threat worldwide.
Based on this knowledge, in this study we investigated
whether Ta1 treatment would act as adjuvant by regulating
human monocyte-derived DC responsiveness to TLRs trig-
gered on one hand by viral nucleic acids (TLR3 and
TLR7/8) and on the other hand by bacterial components
(TLR2 and TLR4) by performing a comparative analysis.
Our results identified an opposite effect of Ta1 on DC stim-
ulated with viral or bacterial TLR agonists. In particular,
Ta1 synergized with viral stimuli to trigger DC maturation
and release pro-inflammatory mediators, while a dampened
phenotype was observed upon bacterial TLR2 and
TLR4 stimulation. These findings perfectly matched what
was found upon DC infection with pandemic H1N1
2009 Flu A virus (also known as ‘swine Flu’) or live Mycobac-
terium bovis Bacillus Calmette--Guerin (BCG), with the
implication that this aspect may have on clinical and vaccinal
applications of this drug.
2. Materials and methods
2.1 DC preparation
Monocyte-derived DC were prepared as previously des-
cribed [24] under a protocol approved by Istituto Superiore
di Sanit!a Review Board (CE/13/387). Briefly, peripheral
blood mononuclear cells were isolated from freshly collected
buffy coats obtained from 12 different healthy, voluntary
blood donors (Blood Bank of University ‘La Sapienza,’
Rome, Italy) by density gradient centrifugation using
Lympholyte-H (Cedarlane, Hornby, Ontario, Canada).
Monocytes were purified by positive sorting using anti-
CD14-conjugated magnetic microbeads (Miltenyi, Bergisch
Gladbach, Germany). The recovered cells were > 95%
CD14+, as determined by flow cytometry with an
anti-CD14 antibody (Ab) (clone #M5E2, BD
Bioscience, San Jose, CA). DC were generated by culturing
monocytes for 5 days in six-well tissue-culture plates (Costar
Corp., Cambridge, MA) with a cytokine cocktail composed
of 50 ng/ml GM-CSF and 1000 U/ml IL-4 (R&D Systems,
Abingdon, GB). Cells were plated at 0.5 ! 106 cells/ml in
RPMI 1640 (Lonza, Verviers, Belgium), supplemented with
2 mM L-glutamine, and 15% fetal bovine serum (FBS)
(Lonza, Verviers, Belgium). At day 5, the cells were tested
for their differentiation status by evaluating CD1a expression
(> 90% CD1a+) and lack of CD14 (> 95% CD14-).
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2.2 Viral and bacterial preparation and DC infection
The M. bovis BCG (ATCC 27291) was grown as previously
described [25]. Briefly, bacteria were grown with gentle agita-
tion (80 rpm) in Middlebrook 7H9 broth (Difco Laborato-
ries, Detroit, MI, USA), supplemented with 0.05% Tween
80 (Sigma-Aldrich) and 10%Middlebrook oleic acid albumin
dextrose catalase enrichment (Becton Dickinson, Sparks,
MD, USA) for ~ 1 week. Logarithmically growing cultures
were centrifuged at 800 rpm for 10 min to eliminate clumped
mycobacteria and then washed three times in RPMI 1640.
Mycobacteria were resuspended in RPMI 1640 containing
15% FBS and then stored at -80"C. Bacterial frozen vials
were thawed and bacterial viability was determined by count-
ing the number of colony forming units. All bacterium prep-
arations were tested for endotoxin contamination
(< 1 endotoxin Unit/ml) by the Limulus lysate assay (Lonza).
DC cultures were then infected with a multiplicity of infec-
tion (MOI) of one bacteria/cell as previously described [25].
Where indicated DC were also infected by the pandemic
H1N1 2009 Flu A Virus at MOI of 1. The pandemic
H1N1 (A/Milan/UHSR1/2009 strain) virus was propagated
in embryonated chicken’s eggs and titrated to determine the
50% tissue culture infection dose in Madin--Darby canine
kidney cells using Reed and Muench’s method [26].
2.3 Reagents
Lipopolysaccharide (LPS) (TLR4 agonist) from Escherichia
coli 0111:B4 (Sigma Chemical Co., St. Louis, MO) was
used at a concentration of 1 ng/ml. The combined synthetic
TLR7/8 ligand 3M007 (R-848-Resiquimod analog) was a
kind gift from Dr. Mark A. Tomai (3M Pharmaceutical, St.
Paul, MN) and was used at 1 µM. Polyinosinic--polycytidylic
acid, [poly (I:C)] (Amersham; Piscataway, NJ), a specific
TLR3 ligand, was used at 50 µg/ml. The TLR2 agonist
Pam3CSK4 (Alexis Corp., San Diego, CA) was used at
2 µg/ml. Dose and stimulation time used in this manuscript
were selected by dose--response experiments performed in
kinetic (data not shown).
Where indicated, a 2-h pre-treatment with Ta1 (100 ng/ml,
Sigma-Tau, Italy) was performed on DC before infection or
TLR treatment.
2.4 Flow cytometry analysis
DC (at least 105) were harvested, washed once in PBS
containing 2% FBS and incubated with monoclonal Ab at
4"C for 30 min. To stain DC, monoclonal Abs specific for
CD1a, CD14, CD86, human leukocyte antigen (HLA)-DR,
HLA-I (ABC alleles) together with IgG1 and IgG2a isotype
controls (BD Bioscience), were used as direct conjugates to
different fluorochromes as needed. Fixable Viability Dye
eFluor 780 (eBioscience, San Diego, CA) was also used to
label dead cells. After washing, cells were fixed in 2% formal-
dehyde (PanreacQuimica, Castellar del Valles, Spain) and run
on a FACSCanto (BD Bioscience, San Jose, CA). A total of
30000 cells were analyzed per sample. After gating viable
DC and selecting singlets only, the expression of the analyzed
surface molecules was evaluated by subtracting the mean fluo-
rescence intensity (MFI) values from those of the isotype Ab
controls. Data were analyzed by FlowJo software (TreeStar,
Inc.). The full gating strategy used is shown in Figure 1.
2.5 Cytokine determination
Supernatants of DC cultures were harvested after 24 h of TLR
treatment or infection, filtered with 0.2 µm filtering advices
and stored at -80"C. The production of TNF-a, IL-6 and
IL-8 was then measured by the human inflammation Cyto-
metric Bead Array (CBA) kit (BD Bioscience) on a FACS-
Canto (BD Bioscience) and analyzed by using the FCAP
Array! Software (v. 3.0) (BD Bioscience).
2.6 RNA isolation and real-time PCR quantification
Total RNA was extracted from untreated or treated DC with
RNeasy Mini kit (Qiagen, Inc., Valencia, CA) according to
the manufacturer’s instructions. Reverse transcription was
primed with oligo (dT) and performed with murine leukemia
virus reverse transcriptase (Invitrogen Life Technologies,
Carlsbad, CA, USA) as previously described [27]. Quantitative
PCR assays for glyceraldhehyde-3-phosphate dehydrogenase
(gapdh), IFN-as, IFN-b and IFN-l1 transcripts were done
in triplicates by using the Light Cycler Fast Start DNA
SYBR Green I Master Mix in the presence of 3 mM MgCl2
on a Light Cycler Instrument (Roche Diagnostics,
Mannheim, Germany). Sample values were normalized by
calculating the relative quantity of each mRNA to that of
gapdh using the formula 2-DCt and expressed as mean ± SEM.
2.7 Statistical analysis
Statistical analysis was calculated using the Wilcoxon test for
nonparametric paired data. A p-value £ 0.05 was considered
statistically significant.
3. Results
3.1 Opposite effects of Ta1 on human monocyte-
derived DC response to stimulation of surface-
bound or intracellular TLRs
Among other recognized ligands of self or non-self origin,
viral and bacterial pathogens are sensed in human DC by dif-
ferent sets of TLRs. In particular, viral nucleic acids are
detected by endolysosome-resident TLR3 and TLR7/8, while
cell surface TLR2 and TLR4 recognize different bacterial
components. We evaluated whether the immunomodulatory
potential of Ta1 would regulate TLR-induced DC responses.
Monocyte-derived DC were differentiated in vitro and then
stimulated with different TLR ligands for 24 h in the presence
or absence of a pretreatment with Ta1. To trigger TLR3 and
TLR7/8 pathways, DC were stimulated with the synthetic
analog of double-stranded RNA, poly (I:C) or with imidazo-
quinoline compound 3M007 (analog of Resiquimod),
Dual effect of Thymosin a 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial TLR agonists
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respectively; while TLR2 was activated by Pam3CSK4, a syn-
thetic triacylated lipopeptide that mimics the acylated amino
terminus of Gram-positive bacterial lipopeptide, and
TLR4 by Gram-negative LPS.
The immune phenotype of infected DC was then analyzed
by evaluating both the surface expression of co-stimulatory
molecules, as well as the secretion of pro-inflammatory cyto-
kines in culture supernatants.
Upon exposure of TLR3 and TLR7/8 to their ligands poly
(I:C) and 3M007, respectively, DC induced the co-
stimulatory marker CD86 and class I and II major histocom-
patibility complex (MHC) molecules, which mediate antigen
presentation to T cells and activation of cellular immunity
(Figure 2A,B), and produced high levels of TNF-a, IL-6 and
IL-8, soluble factors critical to mediate inflammation
(Figure 2C).
In line with previous findings, Ta1 alone did not represent
a sufficient stimulus to induce the activation of immature
DC [12,13], conversely the combined exposure to Ta1 and
TLR3 or TLR7/8 ligands remarkably increased the expression
of maturative markers (mainly MHC class I and II molecules)
and the release of TNF-a, IL-6 and IL-8 (Figure 2).
To our surprise, we observed an opposite effect when DC
were stimulated with bacterial components (Figure 3). The
surface expression of CD86, HLA-I and HLA-DR was
highly enhanced on DC upon both TLR2 and
TLR4 triggering. However, their level was not enhanced by
Ta1 co-treatment, but rather decreased when the drug was
present in the cultures, as seen mainly for MHC II molecules
(Figure 3A,B). This counterintuitive trend was even more
pronounced when pro-inflammatory cytokine production
was measured. Hence, TNF-a, IL-6 and IL-8 release was
strikingly reduced in TLR2/4-treated DC in presence of
Ta1 (Figure 3C).
Taken together, these findings may indicate that, while
Ta1 reinforces the inflammatory state of DC upon viral stim-
uli, conversely this molecule may somehow reduce the release
of pro-inflammatory cytokines during bacterial infections.
3.2 Ta1 dampens the response of human monocyte-
derived DC to BCG infection
In light of this view, it is clear how the differential effect of
Ta1 on viral versus bacterial TLR stimulation of DC, could
be reflected in the regulation of vaccine-induced immunity,
providing also that these cells are of key importance in this
context. Thus, we tested whether Ta1 treatment would mod-
ulate the response of human DC also after infection with live
viruses and bacteria, in particular the pandemic H1N1 Flu A
virus or the attenuated mycobacterial vaccine strain BCG.
BCG is the only licensed tuberculosis (TB) vaccine in use at
present and an estimated 100 million children receive BCG
every year globally. However, this empirically attenuated vac-
cine strain imparts only a partial immune protection, thus,
new TB vaccines are urgently needed [28].
Monocyte-derived DC were differentiated in vitro and then
infected with BCG for 24 h in the presence or absence of a
pre-treatment with Ta1. Expression of co-stimulatory mole-
cules and pro-inflammatory cytokine secretion were then
tested (Figure 4). After BCG infection, DC induced the co-
stimulatory marker CD86 and both HLA-I and II molecules
(Figure 4A,B), and produced high levels of the inflammatory
cytokines TNF-a, IL-6 and IL-8 (Figure 4C). Interestingly
and in line with what observed upon TLR2 and
TLR4 stimulation, Ta1 treatment significantly dampened
both expression of maturation markers (mainly HLA-I and
II) (Figure 4A,B) and production of pro-inflammatory media-
tors (Figure 4C). Even if we do not know whether these differ-
ences are biologically relevant, we can hypothesize that BCG-
infected DC, displaying decreased accessory signals for T-cell
activation in the presence of Ta1, would have a reduced effi-
cacy in driving protective vaccine-induced immune responses.
3.3 Ta1 amplifies human monocyte-derived DC
response to Flu infection
Together with BCG, here, we also evaluated Ta1 effect on
human DC response to infection with the pandemic H1N1
2009 Flu A virus (Figure 5).
H1N1 infection upregulated the co-stimulatory marker
CD86 and both HLA-I and II molecules in DC (Figure 5A,
B). However, while HLA-I was strongly induced by H1N1
and not further enhanced by Ta1, HLA-DR and CD86
were slightly expressed on DC upon H1N1 infection and
the presence of Ta1 in culture enhanced the expression level
of both these markers, as seen for TLR3 and TLR7/8 stimu-
lation. Thus, Ta1 treatment was of key importance to drive
a full DC maturation upon H1N1 infection.
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Figure 1. Gating strategy used for monocyte-derived DC
flow cytometry analysis. Monocyte-derived DC were differ-
entiated in vitro for 5 days in the presence of IL-4/GMCSF
cytokine cocktail and then stimulated as described in the
text. Cells were then collected for flow cytometry analysis.
Full gating strategy used for monocyte-derived DC char-
acterization is shown. Untreated or treated DC were
identified by FSC/SSC gating (left panel) and dead cells
excluded by means of FVDye staining (right panel). Dot plots
derived from a representative individual are depicted.
DC: Dendritic cell; FSC: Forward-scattered light; FVDye: Fixable viability dye;
SSC: Side-scattered light.
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Figure 2. Effect of Ta1 on human monocyte-derived DC response to TLR3 and TLR7/8 triggering. DC were treated for 24 h
with the TLR3 agonist poly (I:C) (50 µg/ml) and the TLR7/8 ligand 3M007 (1 µM) in the presence or absence of a 2 h
pre-treatment with Ta1 (100 ng/ml). (A) Expression of the surface molecules HLA-I (ABC), HLA-DR and CD86 was calculated on
live-gated DC by subtracting MFI values obtained from isotype control Abs to those derived from each different experimental
condition. Data are reported as MFI mean ± SEM of six independent experiments. *p = 0.045; zp < 0.002. (B) Flow plots of HLA-
I, HLA-DR and CD86 in live-gated monocyte-derived DC from one representative individual are shown. (C) TNF-a, IL-6 and
IL-8 production was evaluated in DC culture supernatants by CBA analysis. The results represent means of pg/ml values ± SEM
of six independent experiments. *p < 0.04.
ctrl: Untreated control culture; DC: Dendritic cell; MFI: Mean fluorescence intensity; TLR: Toll-like receptor.
Dual effect of Thymosin a 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial TLR agonists
Expert Opin. Biol. Ther. (2015) () 5
Ex
pe
rt 
Op
in.
 B
iol
. T
he
r. D
ow
nlo
ad
ed
 fr
om
 in
for
ma
he
alt
hc
are
.co
m 
by
 A
dv
an
ce
d I
ns
titu
te 
of 
Sa
nit
a o
n 0
6/2
2/1
5
Fo
r p
ers
on
al 
us
e o
nly
.
M
FI 100
150
200
50
0
100
150
200
250
300
50
0 0
20
40
60
80
100
120
A.
HLA-I HLA-DR CD86
Tα I
Ctrl TLR2 TLR4 Ctrl TLR2 TLR4 Ctrl TLR2 TLR4
* *
100
75
50
25
0
%
 o
f m
ax
100
75
50
25
0
%
 o
f m
ax
104103102101100 104103102101100 104103102101100
HLA-I
B.
HLA-DR CD86
Tα I
TLR4 agonist
TLR4 agonist+Tα I
Ctrl
Tα I
TLR2 agonist
TLR2 agonist+Tα I
Ctrl
pg
/m
l
30000
25000
20000
15000
10000
5000
0
30000
25000
20000
15000
10000
5000
00
3000
6000
9000
C.
*
*
*
*
*
*
TNF-α
Tα I
IL-8IL-6
Ctrl TLR2 TLR4 Ctrl TLR2 TLR4 Ctrl TLR2 TLR4
Figure 3. Effect of Ta1 on human monocyte-derived DC response to TLR2 and TLR4 triggering. DC were treated for 24 h with
the TLR2 agonist Pam3CSK4 (2 µg/ml) and the TLR4 ligand LPS (1 ng/ml) in the presence or absence of a 2-h pre-treatment with
Ta1 (100 ng/ml). (A) Expression of the surface molecules HLA-I (ABC), HLA-DR and CD86 was calculated on live-gated DC by
subtracting MFI values obtained from isotype control Abs to those derived from each different experimental condition. Data
are reported as MFI mean ± SEM of six independent experiments. *p = 0.012. (B) Flow plots of HLA-I, HLA-DR and CD86 in live-
gated monocyte-derived DC from one representative individual are shown. (C) TNF-a, IL-6 and IL-8 production was evaluated
in DC culture supernatants by CBA analysis. The results represent means of pg/ml values ± SEM of six independent
experiments. *p < 0.04.
CBA: Cytometric bead array; Ctrl: Untreated control culture; DC: Dendritic cell; MFI: Mean fluorescence intensity; TLR: Toll-like receptor.
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In line with previous data showing that the pandemic strain
induces a weak pro-inflammatory cytokine response in DC
likely to escape host immune defense [29], we found an almost
undetectable level of TNF-a, IL-6 and IL-8 in culture
supernatants of H1N1-infected DC, that was not further
enhanced upon Ta1 treatment (data not shown). Further-
more, it was also reported that the H1N1 strains are very sen-
sitive to the anti-viral action of type I and III IFNs, IFN-a /b
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Figure 4. Ta1 dampens the activation of human monocyte-derived DC to BCG infection. DC were left untreated or infected
for 24 h with BCG (MOI = 1) in the presence or absence of a 2-h pre-treatment with Ta1 (100 ng/ml). (A) Expression of the
surface molecules HLA-I (ABC), HLA-DR and CD86 was calculated on live-gated DC by subtracting MFI values obtained from
isotype control Abs to those derived from each different experimental condition. Data are reported as MFI mean ± SEM of six
independent experiments. *p < 0.05. (B) Flow plots of HLA-I, HLA-DR and CD86 in live-gated monocyte-derived DC from one
representative individual are shown. (C) TNF-a, IL-6 and IL-8 production was evaluated in DC culture supernatants by CBA
analysis. The results represent means of pg/ml values ± SEM of six independent experiments. *p = 0.036; zp < 0.04.
BCG: Bacillus calmette--guerin; CBA: Cytometric bead array; Ctrl: Untreated control culture; DC: Dendritic cell; MFI: Mean fluorescence intensity.
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Figure 5. Ta1 amplifies human monocyte-derived DC response to H1N1 infection. DC were left untreated or infected for 24 h
with H1N1 influenza A strain (MOI = 1) in the presence or absence of a 2-h pretreatment with Ta1 (100 ng/ml). A. Expression
of the surface molecules HLA-I (ABC), HLA-DR and CD86 was calculated on live-gated DC by subtracting MFI values obtained
from isotype control Abs to those derived from each different experimental condition. Data are reported as MFI mean ± SEM
of six independent experiments. *p < 0.04. B. Flow plots of HLA-I, HLA-DR and CD86 in live-gated monocyte-derived DC
derived from one representative individual are shown. C. The transcription of ifn-as (multiple subtypes), ifn-b and ifn-l 1 was
analyzed by real-time quantitative RT--PCR. Quantification data are normalized to the level of the housekeeping gene gapdh
by using the 2-DCt equation. Data are shown as mean ± SEM of six independent experiments. *p < 0.04.
BCG: Bacillus calmette--guerin; Ctrl: Untreated control culture; DC: Dendritic cell; MFI: Mean fluorescence intensity; MOI: Multiplicity of infection.
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and IFN-ls respectively [29], even if with different specific-
ities [26]. It was of great interest to find that Ta1 treatment,
conversely to what found for IFN-b, specifically and signifi-
cantly promoted IFN-as and IFN-l 1 transcription
(Figure 5C), two cytokines that display a great anti-viral poten-
tial on the pandemic Flu A strain, thus amplifying host-
destroying mechanisms to contain the infection process.
4. Discussion
Several clinical applications and conditions demand progress in
adjuvant research and development. In particular, new vaccine
candidates, such as those comprising poorly immunogenic
antigens of HIV, or vaccines for TB, requiring effective T-cell
responses, will take advantage from adjuvants that enable these
responses. Vaccines targeting antigenically diverse pathogens
(such as Flu virus) can benefit from adjuvants that enhance
immune response broadening, enabling vaccines to induce
immunity to antigenic variations of a particular pathogen. In
the aging population, adjuvanted vaccines may play a role in
boosting protective immune responses. Last but not least, the
emerging field of therapeutic vaccines, both for cancer and
infectious diseases, will require adjuvants or pharmacological
enhancers to amplify and direct effective immune responses.
In this context, TLR ligands has long been considered as
immune response modifiers for their ability to address and reg-
ulate key immune cell types such as DC, B cells and
T lymphocytes and increasing interest has been growing to
use natural ligands or synthetic agonists for well-defined
TLRs as adjuvants, either alone or with various formula-
tions [30]. In particular, TLRs, upon recognition of pathogen-
derived molecular patterns, initiate a series of signaling
programs that execute the first line of host defense necessary
for killing infectious microbes. In addition, their signaling
simultaneously induces maturation of DC, responsible for
alerting induction of the second line of host defense, the so-
called adaptive immunity [15]. The plasticity of DC has brought
this cell type to a center stage as promising targets for interven-
tion for immunotherapy and vaccine development and shift the
emphasis from the ‘antigen or epitope’ toward the ‘adjuvant.’
In this regard, the synthetic peptide Ta1 has been exam-
ined worldwide as immunomodulatory agent unveiling its
highly pleiotropic properties acting as regulator of inflamma-
tion, immunity and tolerance [31].
In patients with lung cancer undergoing radiotherapy
Ta1 showed immune-restorative effects [32,33]. Since then,
numerous experimental and clinical studies have tested the
antitumor activity of Ta1, either alone or in combination
with cytokines and/or chemotherapeutic agents [23,30].
Ta1 was also shown to regulate differentiation of the so-
called suppressor or regulatory T cells (Treg) [10]. Current
knowledge indicates that Treg constitute a pivotal mechanism
of immunological tolerance and their manipulation may
boost responses in cancer and microbial diseases or suppress
those unwanted in autoimmunity and transplantation [34].
Ta1 induced the indoleamine 2,3-dioxygenase activity in
plasmacytoid DC in a TLR9 and type I IFN-dependent man-
ner, thus, promoting the generation of FoxP3-expressing
CD4+CD25+ Treg [35].
The immunotherapeutic potential of Ta1 was evaluated to
treat different viral infectious diseases, such as chronic Hepa-
titis C virus [4] and HIV [5] infections. A recent randomized
controlled clinical trial showed also a trend toward improved
survival in patients affected by bacterial sepsis offering new
hopes in the treatment of this fatal disease [36].
A very good experience for Ta1 came also from the use of
this drug as adjuvant in the Flu vaccine in preclinical studies
and then in large clinical trials, in which Ta1 enhanced Ab
response and lead to a decrease of infections in difficult-to-
treat populations, such as those immunosuppressed due to
age or hemodialysis [23]. Furthermore, during the 2009 pan-
demic H1N1 outbreak, Ta1 was also successfully used as
Flu vaccine enhancer [22].
Investigation of the mechanisms of action of Ta1 at the
cellular level has implicated a number of intracellular signal-
ing pathways in a variety of cells leading to stimulation of
the immune system that can explain the effectiveness of this
biologic; however, one of its central role seems to reside in
the modulation of DC functions. Hence, many studies,
mainly conducted in mice, highlighted how Ta1 modulates
maturation, differentiation and functions of DC [13,35,37].
DC have a crucial role in determining immune outcomes
becoming cells that are either stimulators or suppressors of
T cell responses [38] unveiling their key role in instructing
vaccine-induced immunity. Thus, we recently developed a
novel biological platform based on human primary DC for
the preclinical assessment of novel vaccine strains to predict
their immunological potential within a human context [21].
This system may also represent a good model to stimulate
in vitro the generation of inflammatory DC, a distinct subset
of monocyte-derived DC present in inflammatory conditions
as recently reported by Segura et al. [39].
By using this experimental setting, we tested the capacity of
the Mtb vaccine prototype SO2 to stimulate the immunomod-
ulatory properties of humanmonocyte-derivedDC [21]. Indeed,
despite BCG being the most widely used vaccine in human his-
tory with over 100million doses administered annually, TB still
remains a global health emergency with around two million
new deaths caused by this disease each year [40].
Meta-analysis studies have confirmed that BCG protects
children, providing > 80% efficacy against severe forms of
TB, including tuberculous meningitis and miliary TB. In con-
trast, evidence for protection against pulmonary TB in adoles-
cents and adults remains contentious with very variable
efficacy as reported by clinical trials, observational case--con-
trol studies and contact studies [41]. Thus, improving the effi-
cacy of BCG would be of key importance for cost-effective
and sustainable long-term intervention programs.
Based on these assumptions, here we tested the capacity of
Ta1 as vaccine enhancer by studying the regulation of human
Dual effect of Thymosin a 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial TLR agonists
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monocyte-derived DC functions. Our study investigated
Ta1 action at two levels: first, by evaluating whether this
drug would directly modulate viral and bacterial TLR-
triggered pathways leading to modifications of DC immune
phenotype; then, by exploring whether these immune changes
would occur also in the presence of live viruses or bacteria
such as H1N1 Flu A and BCG, respectively.
Our experimental setting demonstrated that Ta1 is a very
efficient promoter of anti-viral immune responses. Indeed,
here we observed that upon triggering of TLR3 and
TLR7/8, sensing viral nucleic acids, monocyte-derived DC
showed a remarkable increase in the synthesis of TNF-a,
IL-6 and IL-8, pro-inflammatory cytokines critical to stimu-
late a protective Th1 response, when Ta1 was present in cul-
ture (Figure 2). The combined exposure to Ta1 and TLR3 or
TLR7/8 ligands significantly upregulated on DC surface the
expression of HLA-I and II molecules, event that is desirable
for adjuvants since the MHC system is critical for the presen-
tation of specific antigens to T cells.
In accordance with what observed upon stimulation with
synthetic TLR ligands mimicking intermediates of viral repli-
cation, Ta1 amplified DC responses during infection with
the live pandemic H1N1 2009 Flu A virus. It is known that
the pandemic H1N1 virus exhibits a weak ability to induce
DC maturation and the release of pro-inflammatory cytokines
and type I and III IFN, a classical mechanism of virus-induced
immune escape to dampen host responses [29]. Here, we con-
firmed these findings and we further found that, while
Ta1 has no effect on the almost absent Flu-driven TNF-a,
IL-6 and IL-8 production (data not shown), however this pep-
tide promoted the maturation process in DC and the expres-
sion of IFN-as and IFN-l1 transcripts (Figure 5).
Surprisingly, however, Ta1 displayed an opposite trend
when DC were stimulated with bacterial components. Indeed,
differently to what found upon stimulation with viral TLR
ligands or Flu infection, the presence of Ta1 dampened DC
immune phenotype upon stimulation with either TLR2 and
TLR4 ligands or live BCG bacteria (Figures 3 and 4). In par-
ticular, in these experimental conditions, the presence of
Ta1 significantly dropped the expression of MHC class I
and II molecules and the release of the pro-inflammatory
mediators TNF-a, IL-6 and IL-8 indicating that Ta1 may
rather reduce than augment the efficacy in driving protective
vaccine-induced immune responses in the context of BCG
and/or bacterial infection.
5. Conclusions and future perspectives
All together, these results indicate that the usage of
Ta1 might have controversial effects depending on the con-
text in which this molecule is used. This is probably due to
the highly pleiotropic properties of this protein, working on
many components of the inflammatory/anti-inflammatory
cascade at a time, leading to the more various and sometimes
opposite trends in immune-regulation. Using a preclinical set-
ting such as that of human primary monocyte-derived DC to
test or screen adjuvant or immunotherapeutic agents alone or
in conjunction with the target pathogen might be of key
importance to evaluate the immunological outcome of the
chosen compounds in an in vitro model as closest as possible
to the final vaccine recipient.
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